State lawsuits against Purdue have mounted in recent months as governments at all levels have struggled to combat the opioid epidemic - much of which, experts say, was caused by excessive prescription of powerful painkillers like OxyContin.
The Connecticut-based drugmaker said that it has already reduced its sales representative to 200 and has restructured its commercial operation.The drug company said that its sales representatives will longer visit doctors' offices to promote the company's opioid products.
Doctors with opioid-related questions will be directed to its medical affairs department.
Opioids were involved in more than 42,000 overdose deaths in 2016, according to the U.S. Centers for Disease Control and Prevention. But the drug continued to rack up blockbuster sales.
OxyContin maker Purdue Pharma said it will tell doctors about its decision Monday.
Among other opioid producers, Endo International Plc agreed in July to pull its Opana ER painkiller after the Food and Drug Administration called for its withdrawal.
At least 14 states have sued Purdue, and many cities including Greenfield and Springfield in Western Massachusetts.
Purdue's sales representatives will now focus on the Symproic drug created to treat opioid-induced constipation, and other non-opioid products.
Alabama last Tuesday became the latest state to file a lawsuit accusing the private CT company of fueling the USA epidemic by misrepresenting the risks and benefits of opioids.
A surge in prescriptions of opioids followed the 1995 release of the drug when about 90 million opioid prescriptions were filled.
Purdue's promotions exaggerated the drug's safety and risks of addiction, leading to lawsuits and federal investigations. Other lawsuits remain, and a key demand in the remaining lawsuits was that Purdue Pharma drop its direct marketing efforts for pain medications. It agreed in 2015 to pay $24 million to resolve a lawsuit by Kentucky.